tiprankstipranks
Cartesian Therapeutics, Inc. (RNAC)
NASDAQ:RNAC
US Market
RNAC
Cartesian Therapeutics
RESEARCH TOOLSreports
Want to see RNAC full AI Analyst Report?

Cartesian Therapeutics (RNAC) Income Statement

1,164 Followers

Cartesian Therapeutics Income Statement

Last quarter (Q1 2026), Cartesian Therapeutics's total revenue was $78.00K, a decrease of -92.91% from the same quarter last year. In Q1, Cartesian Therapeutics's net income was $-39.18M. See Cartesian Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 2.80M$ 38.91M$ 26.00M$ 110.78M$ 85.08M
Gross Profit
$ 2.80M$ 38.91M$ 26.00M$ 108.74M$ 85.08M
Operating Expenses
$ 89.50M$ 82.81M$ 112.42M$ 94.20M$ 89.67M
Depreciation and Amortization
$ 0.00$ 1.15M$ 843.00K$ 2.04M$ 1.72M
EBITDA
$ -86.70M$ -75.99M$ -235.03M$ 39.84M$ -5.16M
Operating Income
$ -86.70M$ -43.90M$ -86.42M$ 14.54M$ -4.60M
Other Income/Expenses
$ -52.79M$ -33.24M$ -152.29M$ 20.23M$ -5.12M
Pretax Income
$ -139.50M$ -77.14M$ -238.71M$ 34.77M$ -9.72M
Net Income
$ -130.30M$ -77.42M$ -219.71M$ 35.38M$ -25.69M
Per Share Metrics
Basic EPS
$ -5.02$ -2.99$ -49.76$ 7.33$ -6.74
Diluted EPS
$ -5.02$ -3.29$ -49.76$ 3.00$ -6.60
Weighted Average Shares Outstanding
 25.97M 25.91M 5.17M 4.02M 3.18M
Weighted Average Shares Outstanding (Diluted)
 25.97M 23.69M 5.17M 4.05M 3.18M
Currency in USD

Cartesian Therapeutics Earnings and Revenue History